Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | KIF11 | P52732 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624707 | 0.99 | AHR (0.43) | AHRACSS2KMT2ACYP19A1KIF11 | |
| SCHEMBL4626920 | 0.99 | AHR (0.43) | AHRACSS2KMT2ACYP19A1KIF11 | |
| SCHEMBL4625813 | 0.94 | CYP19A1 (0.37) | AHRACSS2KMT2ACYP19A1SMN1; SMN2 | |
| SCHEMBL4625906 | 0.94 | CYP19A1 (0.37) | AHRACSS2KMT2ACYP19A1SMN1; SMN2 | |
| SCHEMBL4625644 | 0.93 | NR1H2 (0.35) | AHRACSS2KMT2ACYP19A1SMN1; SMN2 | |
| SCHEMBL4627027 | 0.84 | KIF11 (0.41) | AHRKMT2AKIF11KCNH2LMNA | |
| SCHEMBL29205 | 0.79 | CA4 (0.54) | AHRACSS2KMT2AKIF11KCNH2 | |
| SCHEMBL28797 | 0.79 | CA4 (0.54) | AHRACSS2KMT2AKIF11KCNH2 | |
| SCHEMBL4626091 | 0.75 | ALDH1A1 (0.35) | KMT2ALMNA | |
| SCHEMBL4625876 | 0.74 | ELANE (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401851-B8 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | FEBIT HOLDING GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1401851-B1 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | FEBIT BIOTECH GMBH (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-7355036-B2 | Two-stage protective groups for the synthesis of biopolymers | FEBIT AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | MR. CHRISTOPHER SEAGON, ESQ. (DE) | 2004-10-07 | — | — | US | disclosed |
| EP-1401851-A1 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | Febit AG (DE) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003004510-A1 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | FEBIT AG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | CTRB2, OGG1, CPB2 | AHR 1051/4885ACSS2 2355/4885KMT2A 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.